The outbreak of obesity, metabolic syndrome and diabetes has driven NAFLD as the first cause of liver diseases. Management of NAFLD in clinical practice is surrounded by uncertainties and clinical dilemmas that motivate us to explore them beyond the borders of hepatology. Liver outcomes of NAFLD like cirrhosis, liver cancer or liver transplantation would appear in a small percentage of the large population suffering from NAFLD giving the opportunity to define better skills and tools for decision-making. The conference will be an excellent place to discuss epidemiology and pros and cons for population screening together with the analysis of individual risk factors from genes to environment. NAFLD as a systemic disease is associated with several pathological conditions from cardiovascular to kidneys and lung diseases.
Diagnostic methods would be addressed, including liver histology as well as non-invasive methods. Defining safe and accurate non-invasive diagnostic methods are an unmet need that is mandatory to resolve for the improvement of knowledge and management of this entity. Mechanism of disease progression could allow us to look for new therapeutic targets. Lastly, patient selection for therapeutic interventions starting with approaches to promote weight loss using diet and physical exercise interventions to bariatric surgery will be reviewed. In non-responders patients, emerging pharmacologic options would fill the gap to increase success rate in NASH resolution.
Physicians with interest in Hepatology.
Researchers in the field of NASH.
Young researchers and trainees.
3 days of cutting edge clinical research on NASH.
7 sessions covering the latest on NASH diagnosis and management.
Gather and network with renowned specialists and leading experts
NASH, Epidemiology, Disease History and Prognostic, Diagnosis Progress, Disease Management
The EASL Monothematic Conference Conference: “NASH: Beyond the acronym, certainties and clinical dilemmas” is designated for a maximum of (or ‘for up to’) 12 hours of European external CME credits.
Prof. Jean-François Dufour, Bern, Switzerland
Dr Manuel Romero-Gomez, Sevilla, Spain,
Prof. Vlad Ratziu, Paris, France
Discover our clinical practice guidelines
Next EASL events
Ground-breaking €34 million project to develop better test for liver disease
NEW METHOD INCLUDING QUANTIFICATION OF CIRCULATING MIRNAS ALLOWS EFFICIENT IDENTIFICATION OF NASH.